← Leaderboards
Eva Corey
University Of Washington
$2,497,094
Attributed
$2,497,094
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $331.7K · FY2007–25$500K$375K$250K$125K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,497,094 · 5
By mechanism
P01$1,178,972 · 3
R01$948,480 · 1
R21$369,642 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Washington
Same institution · by research overlap
- Stephen R Plymate$6,213,858
- Robert Vessella$14,829,966
- Edward A Clark$26,060,534
- John K Amory$37,632,597
- Cecilia M. Giachelli$21,973,061
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateTumorIn VitroResistanceAndrogen ReceptorResearch PersonnelSignal TransductionProgramsDesignSamplingXenograft ProcedureTissuesSerumResourcesPre-ClinicalPreclinical StudyCastration Resistant Prostate CancerHistologicIn Situ HybridizationBiologicalAbirateroneBaseClinicAutopsy
Grant awards (13)
PDX/Biospecimen Core$331,742
P01 · FY2025 · CA · contact PI
Core B: PDX/Biospecimen Core$174,376
P01 · FY2023 · CA · contact PI
Core B: PDX/Biospecimen Core$174,201
P01 · FY2022 · CA · contact PI
Core B: PDX/Biospecimen Core$159,968
P01 · FY2021 · CA · contact PI
Core B: PDX/Biospecimen Core$159,968
P01 · FY2020 · CA · contact PI
Core B: PDX/Biospecimen Core$178,717
P01 · FY2019 · CA · contact PI
Exploring high-does testosterone as a potential treatment for abiraterone-resistant prostate cancer$201,623
R21 · FY2017 · CA · contact PI
Exploring high-does testosterone as a potential treatment for abiraterone-resistant prostate cancer$168,019
R21 · FY2016 · CA · contact PI
Roles of Nemo-like kinase in CaP and its effects on androgen receptor signaling$237,120
R01 · FY2010 · CA · contact PI
Roles of Nemo-like kinase in CaP and its effects on androgen receptor signaling$237,120
R01 · FY2009 · CA · contact PI
Roles of Nemo-like kinase in CaP and its effects on androgen receptor signaling$237,120
R01 · FY2008 · CA · contact PI
Roles of Nemo-like kinase in CaP and its effects on androgen receptor signaling$237,120
R01 · FY2007 · CA · contact PI
CaP AND GROWTH DYSREGULATION IN BONE$0
P01 · FY2002 · CA